Semaglutide(Sinopep Allsino Bio Pharma)

司美格鲁肽（江苏诺泰澳赛诺生物）

Report date: 2026/04/09 14:28:35

Base Information

Drug NameSemaglutide(Sinopep Allsino Bio Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSinopep Allsino Bio Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinopep Allsino Bio Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[5] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A